Zebrafish models of human motor neuron diseases: Advantages and limitations by Babin, P.J. et al.
Progress in Neurobiology 118 (2014) 36–58Zebrafish models of human motor neuron diseases:
Advantages and limitations
Patrick J. Babin a,*, Cyril Goizet a,b, Demetrio Raldúa c,*
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A B S T R A C T
Motor neuron diseases (MNDs) are an etiologically heterogeneous group of disorders of neurodegenerative
origin, which result in degeneration of lower (LMNs) and/or upper motor neurons (UMNs).
Neurodegenerative MNDs include pure hereditary spastic paraplegia (HSP), which involves specific
degeneration of UMNs, leading to progressive spasticity of the lower limbs. In contrast, spinal muscular
atrophy (SMA) involves the specific degeneration of LMNs, with symmetrical muscle weakness and
atrophy. Amyotrophic lateral sclerosis (ALS), the most common adult-onset MND, is characterized by the
degeneration of both UMNs and LMNs, leading to progressive muscle weakness, atrophy, and spasticity. A
review of the comparative neuroanatomy of the human and zebrafish motor systems showed that, while
the zebrafish was a homologous model for LMN disorders, such as SMA, it was only partially relevant in the
case of UMN disorders, due to the absence of corticospinal and rubrospinal tracts in its central nervous
system. Even considering the limitation of this model to fully reproduce the human UMN disorders,
zebrafish offer an excellent alternative vertebrate model for the molecular and genetic dissection of MND
mechanisms. Its advantages include the conservation of genome and physiological processes and
applicable in vivo tools, including easy imaging, loss or gain of function methods, behavioral tests to
examine changes in motor activity, and the ease of simultaneous chemical/drug testing on large numbers of
animals. This facilitates the assessment of the environmental origin of MNDs, alone or in combination with
genetic traits and putative modifier genes. Positive hits obtained by phenotype-based small-molecule
screening using zebrafish may potentially be effective drugs for treatment of human MNDs.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Historically, the term ‘‘motor neuron diseases’’ (MNDs) refers to
disorders caused by the degeneration of motor neurons (MNs)
located at anterior horn in the spinal cord or at the brainstem
motor nuclei, with secondary Wallerian degeneration of motor
axons (Desai and Olney, 2009). In fact, MNDs constitute an
expanding, heterogeneous group of developmental and neurode-
generative disorders. Recently, substantial progress has been made
in deciphering the molecular bases of numerous inherited
conditions (Brown and Phil, 2000; Dion et al., 2009; Fink, 2013;
Van Damme and Robberecht, 2009). These disorders are anatomi-
cally subdivided, depending on whether they involve upper motor
neurons (UMNs), i.e. premotor neurons with soma located in
higher regions of the brain and conveying descending commands
for movement, lower motor neurons (LMNs), i.e. brain stem cranial
motor nuclei and spinal MNs, or both (Brown and Phil, 2000). The
UMNs of the central nervous systems (CNS) originate in the motor
cortex or brainstem and relay motor information to the LMNs.
LMNs are located in the cranial motor nuclei and spinal cord and
relay impulses from the UMNs to the muscles at neuromuscular
synapses to innervate the skeletal muscles (Pratt et al., 2012). UMN
symptoms generally include weakness, speech problems, overac-
tive tendon reflexes, spasticity, Hoffmann signs, Babinski signs,
clonus, and inappropriate emotionality. LMN symptoms also
include weakness, as well as attenuated reflexes, cramps,
twitching, and muscle wasting. Considerable overlaps of clinical,
paraclinical, and physiopathological characteristics may be ob-
served between these entities, leading to persistent difficulty in
establishing a precise diagnosis in some patients and raising
controversies about the classification of these disorders.
Animal models of human MNDs, mostly rodents, but also the
fruit fly (Drosophila melanogaster) and the nematode worm
(Caenorhabditis elegans), have been used in attempts to understand
the neurobiological basis of MNDs and predict successful
treatment strategies (Bebee et al., 2012; Grice et al., 2011; Hirth,
2010; Lanson and Pandey, 2012; McGoldrick et al., 2013; Sleigh
et al., 2011). The zebrafish (Danio rerio) is a vertebrate species, with
a similar overall nervous system organization to humans, and is
increasingly used to model human diseases (Seth et al., 2013). It
represents a powerful experimental model for studying neuroge-
netic disorders and MNDs, due to the high conservation of genesimplicated in neurodegenerative diseases and physiological
processes involved in nervous system morphogenesis and
maintenance (Bandmann and Burton, 2010; Becker and Rinkwitz,
2012; Kabashi et al., 2011a; Xi et al., 2011). In view of the current
emphasis on high-throughput screening to identify genetic
interactions and pharmacological therapies, the zebrafish model
has become an attractive alternative to rodents, thanks to lower
costs and less time-consuming experiments. This review sum-
marizes current knowledge of the comparative neuroanatomy of
human and zebrafish motor systems. A comprehensive overview of
current knowledge of human genes and factors involved in MNDs
and the use of zebrafish in investigating the biology of human
illness are also presented. The validity of the zebrafish model for
acquiring knowledge of specific components of MNDs is also
discussed.
2. Comparative neuroanatomy of human and zebrafish motor
systems
Human motor systems are organized hierarchically in three
levels of control: spinal cord, brainstem, and motor cortex. There is
a clear division at each level of control between MNs innervating
axial muscles and those innervating limb muscles. Zebrafish have
at least twenty different neuronal populations in the brain
projecting to the spinal cord, mostly located at the brainstem
(Becker et al., 1997). However, an important difference between
teleost fish species and mammals is that there are no direct
telencephalic projections to the spinal cord. Whereas the
corticospinal tract (CST) is seen as an adaptation for fine motor
control of the limbs in mammals (Iwaniuk and Whishaw, 2000),
the brainstem organization of neurons with descending axons is
generally more highly conserved among other vertebrates
(Goulding, 2009).
2.1. Spinal cord
The human motor nuclei in the spinal cord, the lowest level in
the hierarchical organization, are arranged along a medial-lateral
axis according to function. The ventral medial motor column
(MMC) projects to the axial muscles in the neck and back, the
hypaxial motor column projects to the hypaxial muscles in the
ventral body wall, and the dorsal lateral motor columns (LMC)
Fig. 1. Schematic summary of the topography of trunk spinal motor neurons (MNs)
and the muscles they innervate in a zebrafish larva. For the sake of simplicity, only
the innervation of primary (PMNs) and secondary motor neurons (SMNs) on one
side is shown. Upper graph is a lateral view at the spinal cord level with anterior
part to the left and dorsal part to the top. At the trunk level, zebrafish larvae present
a superficial monolayer of slow muscle fibers (red) and in deep portion of the
myotome only fast muscle fibers are present (dark green). Larval pectoral fin
musculature contains no slow fibers until approximately 7 mm body length. Fast
muscle fibers of abductor and adductor muscles and endoskeletal disk of the fin are
represented in dark green and blue, respectively. At the mid-trunk level, somata of
the PMNs (bright green) are located at the dorsal most region of the motor column
of the spinal cord. Axons from PMNs project only on fast muscle fibers (dark green).
Somata of SMNs (blue) are smaller, more numerous and are located more ventral
than those of PMNs. Axons from these MNs project both to the fast and the slow
muscle fibers. Finally, at the pectoral fin level an additional pool of spinal MNs is
present (red). These ventral MNs (VMNs) innervating the abductor and adductor
muscles at the pectoral fin level have the somata at the most ventral region of the
ventral horn. Axon of the Mauthner (M) cell running in the spinal cord is indicated
in dark red.
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topographic map of the motor nuclei of the spinal cord, arranged in
different motor columns innervating different groups of muscles is
also present in other mammals, reptiles, and birds, but not in other
vertebrates (Fetcho, 1992). Spinal LMNs, innervating muscles
fibers, are highly diverse in terms of morphology, connectivity, and
functional properties and differ significantly in their response to
disease (Kanning et al., 2010). Alpha MNs (a-MNs) innervate
extrafusal muscle fibers and drive in-muscle contraction. Gamma
MNs (g-MNs) innervate intrafusal muscle fibers of the muscle
spindle and are involved in proprioception. a-MNs, the most
abundant class of spinal MNs, can in turn be classified in three
subtypes, according to the contractile properties of the motor units
that they form with target muscle fibers: slow-twitch, fatigue
resistant (S), fast-twitch, fatigue resistant (FR), and fast-twitch,
fatigable (FF) (Burke et al., 1973). FF-subtype MNs have large cell
bodies and large-diameter, fast-conducting axons, while the S-
subtype has the smallest cell bodies and axons. FF MNs seem to be
the most sensitive to multiple degenerative disorders, including
spinal muscular atrophy (SMA), amyotrophic lateral sclerosis
(ALS), and aging.
Zebrafish spinal MNs may be divided into primary and
secondary classes, based on when they differentiate and innervate
their target musculature (Eisen et al., 1986; Myers et al., 1986).
Primary motor neurons (PMNs) are larger, appear during
gastrulation, and undergo axogenesis during the first day of
development (Lewis and Eisen, 2003). Three to four individual
PMNs may be identified in each spinal hemisegment by their cell-
body positions, axonal trajectories, and electrical membrane
properties (Moreno and Ribera, 2009). Caudal primary motor
neurons (CaP MNs) innervate the ventral trunk musculature,
middle primary motor neurons (MiP MNs) innervate dorsal trunk
musculature, and rostral primary motor neurons (RoP MNs)
innervate muscle fibers in between. A fourth class, variable
primary motor neurons (VaP MNs), typically undergoes apoptosis
by 36 h post fertilization (hpf) (Eisen et al., 1990), innervating
muscle fibers located between the territory of rostral and middle
PMNs. In a recent paper, Menelaou and McLean (2012) analyzed
motor unit properties and recruitment in larval zebrafish, finding
two different types of RoP MNs: ventrally- and dorsally-projecting
RoPs MNs. Although PMNs exhibit collaterals projecting off the
main axons and ramify extensively throughout the deep muscula-
ture, some PMNs also present collaterals within the spinal cord
(Menelaou and McLean, 2012). PMNs, located in the dorsal part of
the motor column, have been classified by their electrical
properties as the tonic class of zebrafish spinal MNs, with a high
spike threshold, high-frequency tonic spiking, and limited spike-
frequency adaptation in response to suprathreshold current
injection (Menelaou and McLean, 2012). Secondary motor neurons
(SMNs), located more ventrally in the motor column, are smaller,
more numerous, appear later, and typically have thinner axons
than PMNs. Menelaou and McLean (2012) also categorized SMNs
according to the extent of their dorsoventral muscle innervation.
Thus, the dorso-ventrally-projecting SMNs, the most dorsally
located SMNs, exhibit an innervation field in both the dorsal and
ventral musculatures, while the ventrally-projecting secondary
motor neurons (vS), with the soma located immediately below the
dorso-ventrally-projecting SMNs, have a ventrally-restricted
arborization field. These two types of SMNs exhibit more extensive
branching off the main axons deep in the muscle tissue, suggesting
that they preferentially activate fast muscles. Finally, the dorsally
projecting SMNs, with the soma located below the vS, exhibit an
innervation field in the dorsal musculature, with the most
extensive arborization in fast skeletal muscle. In addition,
Menelaou and McLean (2012) demonstrated two additional classes
of SMNs with a common anatomical feature: the presence of amajor collateral axon running superficially along the intermyoto-
mal boundary. When SMNs were classified on the basis of their
electrophysiological properties, two subtypes were reported. On
one hand, the chattering class of spinal MNs, with a lower spike
threshold than the tonic class and a significant spike frequency
adaptation during prolonged subthreshold current injection. On
the other hand, the bursting class of spinal MNs, with a lower spike
threshold, that produce slow membrane potential changes.
Although there were no exclusive correspondences between these
two electrophysiological classes of SMNs and any morphological
classes of SMNs, bursting MNs tended to be more ventral than
chattering MNs.
The somata of zebrafish PMNs and most SMNs are located in the
spinal cord motor column. Moreover, MNs located in the ventral
most region of the ventral horn innervate the paired fins, and in the
case of the pectoral fin MNs their cell bodies are located in
segments three through six (Myers, 1985; Thorsen and Hale, 2007).
Such teleost fish appendicular MNs do no segregate into a lateral
motor column, and abductor an adductor MNs are mingled within
ventral MNs (Fig. 1) (Thorsen and Hale, 2007; Murakami and
Tanaka, 2011). In fact, although fin MNs present some similarities
with SMNs, as a similar size of the soma and thicknes of the axons,
they represent a distinct class of spinal MNs (Myers, 1985). Thus,
islet 1 is not expressed in the zebrafish pectoral fin MNs, but is
expressed strongly in SMNs (Higashijima et al., 2000). PMNs have
not been described in amniotes, thus human a-MNs may be more
similar to SMNs (Beattie et al., 1997). No g-MNs have been
described in zebrafish, which do not have intrafusal muscle fibers.
Axial motor structures formed the primitive motor apparatus of
vertebrates, consisting of a rostro-caudal series of myomeres
Fig. 2. Schematic representation of the ventromedial brainstem descending
pathways in humans and zebrafish. For the sake of simplicity, only the brainstem
nuclei and descending pathways on one side are shown. In humans, fibers (black lines)
arising from the reticular formation (RF), vestibular nuclei (VN), and superior
colliculus (SuC) form the reticulospinal, vestibulospinal, and tectospinal tracts,
respectively. These fibers descend bilaterally in the ventral medial motor column
(MMC) of the spinal cord, projecting mainly onto interneurons (IN), but also directly
into some spinal motor neurons (MNs) innervating epaxial muscles of the dorsal body
region. In zebrafish, fibers arising from the RF, VN, and nucleus of the medial
longitudinal fasciculus (nMLF) descend from the hindbrain along the medial
longitudinal fascicle (MLF), running through the spinal cord as a prominent
ventromedial fascicle (VMF). These fibers project at the spinal cord level mainly
onto collateral or ipsilateral inhibitory and excitatory IN, as well as directly into some
spinal MNs innervating the axial muscles. Although a tectobulbar tract is present (not
shown) in zebrafish, no tectospinal tract has been detected.(Fetcho, 1992). This myomeric musculature is also present in most
anamniotic vertebrates, including zebrafish. The myomeric mus-
culature in zebrafish is divided into two major types of muscle
fibers. Slow fibers, forming a superficial monolayer on the surface
of the myotome, are well-equipped for oxidative phosphorylation
and more resistant to fatigue. Fast fibers, in the deep portion of the
myotome, are more fatigable, as they rely on anaerobic glycolysis
for ATP generation (Welsh et al., 2009). Each fast fiber is innervated
by a single PMN and up to 4 SMNs, whereas each slow fiber is
innervated by several SMNs (Westerfield et al., 1986). Therefore
the two groups of fibers can be differentially controlled and
perform different functions. Slow fibers are activated during slow
sustained swimming, whereas fast fibers only become active
during rapid swimming or escape movements (Fetcho, 1992).
Electrophysiological evidence indicates that slow fibers are tonic
fibers, homologous to the tonic fibers described in the mammalian
extra-ocular muscle and are, therefore, not the homologs of
mammalian slow twitch muscle, while fast fibers are a twitch-fiber
type (Buss and Drapeau, 2002). Molecular and histochemical
studies have not made this distinction, simply classifying fibers on
the basis of the expression of slow or fast heavy chain myosin
isoforms. One question that arises is whether it is appropriate to
compare fast, i.e. twitch, and slow, i.e. tonic, muscle development in
zebrafish with fast and slow twitch muscle development in
mammals. Moreover, different subtypes of SMNs have been
described in the juvenile/adult zebrafish motor column, related
to the types of muscle fibers they innervate (Ampatzis et al., 2013;
Gabriel et al., 2011). In spite to the above described differences,
skeletal muscle fibers in zebrafish share many molecular and
histological features with mammalian muscle fibers, including
preservation of the components of the dystrophin-associated
glycoprotein complex, the excitation-contraction coupling ma-
chinery and the contractile apparatus (Gibbs et al., 2013).
2.2. Brainstem
The human brainstem contains many groups of UMNs
projecting to the spinal cord through two main systems: the
medial and lateral brainstem pathways. These two descending
pathways control different groups of spinal neurons and muscles.
The ventromedial brainstem descending pathways, phylogeneti-
cally the oldest component of the human descending motor
systems, consist of the reticulospinal, vestibulospinal, and
tectospinal tracts. The fibers arising from the brainstem reticular
formation, vestibular complex, and superior colliculus terminate
bilaterally in the MMC of the spinal cord, projecting mainly onto
interneurons and long propriospinal neurons, but also directly
onto some spinal LMNs innervating epaxial muscles in the dorsal
body region (Fig. 2A). The medial pathways provide the basic
postural control system for head, neck, trunk, and proximal limb
movements (Ghez and Krakauer, 2000; Lemon, 2008). The main
dorsolateral brainstem descending pathway is the rubrospinal
tract, originating in the magnocellular portion of the red nucleus in
the midbrain. In humans and rats, the rubrospinal tract descends in
the contralateral dorsal part of the spinal cord LMC, projecting onto
interneurons controlling LMNs at the cervical level of the LMC
(Fig. 3A and B). The lateral pathway is more concerned with
controlling more distal limb segments: elbow and wrist (Lemon,
2008; Purves et al., 2001).
Sixteen distinct brainstem nuclei containing about 220 neurons
in total, including the reticular formation and vestibular nuclei, as
well as the nucleus of the medial longitudinal fascicle, have been
found to project to the zebrafish spinal cord (Becker et al., 1997;
Gahtan et al., 2002). In larval zebrafish, escape-related activity may
be found in 82% of these neurons (Gahtan et al., 2002). The nucleus
of the medial longitudinal fascicle contains the most rostral clusterof zebrafish brainstem neurons, sending ipsilateral projections to
the spinal cord (Kimmel et al., 1982). Although a few rubrospinal
projections have been found in zebrafish (Becker et al., 1997)
(Fig. 3C), the presence of a true rubrospinal tract seems to be
related to the presence of limbs or limb-like structures (Donkelaar,
1988). The octavolateral system in nonelectroreceptive teleosts is
specialized for detecting auditory, vestibular, and lateral line
stimuli. These mechanosensory stimuli are transduced by hair cells
in the otolithic organs, i.e. the utricle, saccule, and lagena,
semicircular canals, i.e. anterior, horizontal, and posterior, and
lateral line systems (Tomchik and Lu, 2005). In adult zebrafish only
neurons from octaval nuclei related to vestibular input, i.e.
magnocellular octaval nucleus, tangential nucleus, anterior octaval
nucleus, and ventrolateral part of descending octaval nucleus, send
ipsilateral projections to the spinal cord, reminiscent of the
vestibulospinal tract in mammals (Becker et al., 1997; Gahtan and
O’Malley, 2003). The presence of a single vestibular nucleus in the
young larvae should be noted (Kimmel et al., 1982). The zebrafish
Fig. 3. Comparison of the lateral descending pathways in humans (A), rats (B), and zebrafish (C). For the sake of simplicity, only the descending pathways on one side are
shown. In humans, fibers from the lateral corticospinal tract (LCST) reach all the levels of the lateral motor column (LMC) of the spinal cord. Although most of these axons form
excitatory synapses with spinal interneurons (IN), some of them project directly onto lower motor neurons (LMN) controlling distal limb muscles. These direct connections
between corticospinal and spinal motor neurons are absent in rodents. Zebrafish do not have any direct telencephalic projections onto the spinal cord. Although the red
nucleus (RN) is present in all three species, a true rubrospinal tract (RST) descending along the contralateral dorsal part of the spinal cord LMC to project onto spinal
interneurons at the cervical level is only present in humans and rats. Dashed lines from the RN to spinal interneurons in C indicate that a few rubrospinal fibers project to the
spinal cord in zebrafish, with no information currently available on the contralateral or ipsilateral position of these fibers.
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the retina and then sends motor outputs to the premotor
reticulospinal system (Sato et al., 2007) and the nucleus of the
medial longitudinal fascicle (NMLF) in the brainstem. Thus, it has
been demonstrated that visual prey capture in larval zebrafish is
controlled by neurons from the NMLF in series with the tectum
(Gahtan et al., 2005). However, no direct tectospinal projections
have been identified in bony fish by retrograde labeling (Sánchez-
Camacho et al., 2001).
Brainstem reticulospinal neurons are phylogenetically con-
served across vertebrates and form a major descending motor
control system that receives convergent sensory inputs and sends
motor commands to spinal circuitry (Kohashi and Oda, 2008). The
zebrafish reticular formation, located in the hindbrain, extends
longitudinally through most of the hindbrain tegmentum, from the
pretrigeminal isthmic tegmentum to the caudal end of the
medulla. This region is the largest source of descending signals
to the spinal cord in zebrafish (Becker et al., 1997). There are about
fifty hindbrain reticulospinal neurons on each side of the brain,
although the best known are the Mauthner neuron and segmental
homologs MiD2 and MiD3, which are involved in initiation and
directional control over the fast escape behavior (Liu and Fetcho,
1999). In mammals it is believed that the Mauthner neurons and
their serial homologs have been replaced by a population of 20–60
‘‘giant neurons’’ in the caudal pontine reticular-formation in the
brainstem (Becker and Becker, 2007). Most of the axons of
reticulospinal neurons, both ipsilaterals and contralaterals, de-
scend from the hindbrain along the medial longitudinal fascicle
(MLF), running through the spinal cord as a prominent ventrome-
dial fascicle (Metcalfe et al., 1986). Many of the axons running
through the MLF show collaterals crossing into the contralateral
spinal cord (Gahtan and O’Malley, 2003).
2.3. Motor cortex
The motor areas in the human cerebral cortex provide the
ability to organize complex motor acts and execute fine precision
movements. The motor cortex UMN axons, descending through the
corticobulbar tract, modulate the activity of the cranial nerve (e.g.
trigeminal, facial, and hypoglossal nuclei) LMNs in the brainstem(Purves et al., 2001). On the other hand, axons of UMNs in the
motor cortex, descending through the CST, modulate the activity of
the spinal LMNs innervating the trunk and limb muscles, both
directly and by modulating the activity of brainstem UMNs. The
CST is a major descending pathway for controlling voluntary
movements. The corticospinal fibers run together with cortico-
bulbar fibers through the internal capsule to reach the ventral
portion of the midbrain. Collaterals of the corticospinal axons
reach some UMNs in the brainstem (e.g. reticular formation, red
nucleus), thus modulating the brainstem descending pathways. In
the medulla, they form the medullary pyramid and about 75% of
the corticospinal fibers cross the midline in the pyramidal
decussation at the junction of the medulla and spinal cord. The
crossed axons descend via the spinal cord LMC, forming the lateral
corticospinal tract (LCST) (Fig. 3), projecting to the cervical and
lumbosacral spinal cord, to control the distal limb muscles of the
hand and foot (Ghez and Krakauer, 2000). Most of the axons
descending through the LCST form excitatory synapses with both
excitatory and inhibitory interneurons. In contrast, a small number
of cortical UMNs, with axons that pass through the LCST, form
excitatory synapses directly on spinal LMNs (Fig. 3A). Most of these
monosynaptic connections are with LMNs controlling the hand
muscles, but the Betz cells have monosynaptic connections to
LMNs controlling the lower limb musculature. Betz cells are large
pyramidal cells located in the primate primary motor cortex,
contributing approximately 3% of the one million axons in the CST
and projecting directly onto spinal LMNs at the lumbosacral level
(Patestas and Gartner, 2006). It is generally believed that, during
evolution, the ability to perform dexterous hand movements
developed in parallel to the establishment of these monosynaptic
cortico-motoneuronal connections (Isa et al., 2007). The cortico-
motoneuronal system is well developed in humans and Old world
monkeys and absent in non-primates (Lemon, 2008; Fig. 3B and C).
Interestingly, the pathogenesis of HSP is characterized by distal
degeneration of the LCST, primarily in the lumbar region (Deluca
et al., 2004), with a significant decrease in the density of both
small- and large-diameter axons. Indeed, the Betz cell axons,
among the largest in the CNS, are the most affected in HSP.
The uncrossed axons descend via the ipsilateral ventral column
of the spinal cord, forming the ventral corticospinal tract (VCST).
Table 1
Comparative neuroanatomy of human and zebrafish motor systems.
Feature Key similarities Key differences and unknowns
Motor Units
Spinal motor neurons U Zebrafish SMNs similar to human a-MNs.
U Different subtypes of MNs, with some located at
specific regions of the spinal cord, innervate axial and
limbs/fins muscles.
U No g-MNs present in zebrafish.
U PMNs have not been described in human.
U Appendicular MNs in teleost fish do no segregate into
a lateral motor column.
Skeletal muscle fibers U Preservation of the dystrophin- associated
glycoprotein complex components.
U Similar excitation-contraction coupling machinery.
U Similar contractile apparatus.
U It is still not well understood if it is appropriate to
compare human and zebrafish fast and slow muscle
fibers.
U Proprioceptors like the muscle spindle are not found in
Zebrafish.
Brainstem
Ventromedial brainstem descending pathway U Fibers from the reticular formation and vestibular
nuclei descend from the hindbrain, projecting at the
spinal cord level mainly onto interneurons, but also
on spinal MNs.
U Fibers from the optic tectum, zebrafish equivalent to
the human superior colliculus, project on the nucleus
of the medial longitudinal fasciculus and the
premotor reticulospinal system, but a direct
tectospinal tract has not been detected.
Dorsolateral brainstem descending pathway U Although a few rubrospinal fibers project to the spinal
cord in zebrafish, a true rubrospinal tract is missing.
Motor cortex
Corticospinal tract U There are no direct telencephalic projections to the
spinal cord, i.e. corticospinal tract, in teleost.Many of these axons contain commissural collaterals crossing into
the contralateral MMC of the spinal cord. VCST axons project onto
interneurons and LMNs in the cervical and lower thoracic spinal
cord, modulating the movement of the neck, upper trunk, and
proximal-forelimb shoulder muscles (Ghez and Krakauer, 2000).
The CST is a phylogenetically new system that first appeared in
mammals and has developed predominantly in primates (Isa et al.,
2007). Thus, there are no direct telencephalic projections to the
spinal cord in teleosts (Becker and Becker, 2007) (Fig. 3C). Whereas
the CST is seen as an adaptation in mammals for fine motor control
of the limbs, the brainstem organization of neurons with
descending axons is generally more highly conserved among
vertebrates, as described above. The absence of corticospinal
UMNs in zebrafish is an important feature to be considered when
this model is proposed for studying UMN diseases such as HSP,
which involves degeneration of the Betz cell axons. However, it is
necessary to consider that cortical UMNs projecting directly onto
LMNs at the lumbosacral level, specifically targeted in some
human UMNs diseases, such as pure HSP, are absent from not only
zebrafish, but also rodent models (Fig. 3B and C). The comparative
neuroanatomy of human and zebrafish motor systems is summa-
rized in Table 1.




The zebrafish model presents many methodological advantages
and extensive collections of useful resources are available
(reviewed in Bandmann and Burton, 2010; Rinkwitz et al., 2011;
Seth et al., 2013) (zfin.org web site, Bradford et al., 2011). These
include tools applicable in vivo, like whole-mount imaging, thanks
to the optical transparency of zebrafish embryos and early larval
stages, methodologies for modulating gene expression, behavioral
tests to examine changes in motor activity, and simplified
simultaneous chemical/drug testing on large number of animals
(for recent reviews see Bandmann and Burton, 2010; Laird and
Robberecht, 2011; Rinkwitz et al., 2011). The fully sequenced
genome is available (Howe et al., 2013), together with molecular
anatomical atlases and collections of transgenic lines expressing
fluorescent proteins under neuron-specific promoters (Bradfordet al., 2011; Flanagan-Steet et al., 2005; Higashijima et al., 2000;
Naumann et al., 2010; Satou et al., 2013; Zelenchuk and Brusé,
2011). Numerous gene knockout lines and their short-term
associated phenotypes (Kettleborough et al., 2013; Varshney
and Burgess, 2013) are now complementary to antisense
morpholino oligonucleotides (AMO) transitory knockdown and
other genome editing methods (Schmid and Haass, 2013), like
transcription activator-like effector nucleases, i.e. TALEN (Bedell
et al., 2012; Sander et al., 2011; Zu et al., 2013), the CRISPR/Cas
system (Hruscha et al., 2013; Hwang et al., 2013; Jao et al., 2013),
and transgenic techniques for conditional gene activation or
inactivation (Ni et al., 2012). These genetic manipulation
techniques are used to investigate the function of a particular
gene in the etiology of developmental and/or neurodegenerative
MNDs. For example, it is possible to validate the effect of human
mutations in zebrafish with function loss or gain methods, using
wild-type (WT) or mutated human gene transcripts and knocking
down the zebrafish ortholog using AMO (for details see Kabashi
et al., 2010a; see Section 3.3 for comments on the genetic
differences between these methodological approaches). However,
the potential zebrafish ortholog target gene, if any, must, at least,
be checked for sequence similarity, gene expression pattern, and
synteny conservation between human and zebrafish. It should be
noted that the teleost ancestor experienced a whole-genome
duplication event at the base of the teleost radiation (Braasch and
Postlethwait, 2012). A subsequent rapid gene loss occurred, with
an average duplicate retention rate across all genes in teleost
genomes estimated to be at 12–24% (Braasch and Postlethwait,
2012), but at variable rates according to the gene function
considered (Schartl et al., 2013). Resulting ohnologs may have
retained their initial subfunctions but also acquired new functions,
i.e. neofunctionalization, and/or duplicated genes may be pre-
served by partitioning ancestral subfunctions between them, i.e.
subfunctionalization (Postlethwait et al., 2004). The genetic
interaction between duplicated genes must be taken in consider-
ation, as recently illustrated with the ALS-associated tardbp genes
(Hewamadduma et al., 2013; Schmid et al., 2013).
The functional relationship between an underlying human
mutation and a disease may be tested experimentally, provided an
ortholog with a conserved function has been identified in the
model organism. The zebrafish model in its early developmental
stages is very useful for establishing a causal link with highly
penetrant mutations caused by loss of function mutations or
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applicable to genes involved in MN morphogenesis and, to a
lesser extent, maintenance. Experiments using zebrafish in early
developmental stages demonstrated the power of this model for
studying important MN development regulators (Birely et al.,
2005; Biswas et al., 2014; Feldner et al., 2005, 2007; Glinka et al.,
2010; Hilario et al., 2009; Hutchinson and Eisen, 2006; Laird et al.,
2010; Lotti et al., 2012; Morimura et al., 2013; Simpson et al., 2009;
Campbell and Marlow, 2013; Tanaka et al., 2007; Schweitzer et al.,
2005; Van Ryswyk et al., 2014), including differential subtype
effects (Hutchinson et al., 2007; Pineda et al., 2006; Seredick et al.,
2012). For example, KBP is a developmental protein involved in
axon structure, outgrowth, and maintenance. Zebrafish kbp
mutants exhibited impaired neurogenesis and early axonal
differentiation, phenomena relevant to the cellular basis of
Goldberg-Shprintzen syndrome (Alves et al., 2010; Lyons et al.,
2008).
Mutations leading to systemic metabolic defects and/or the
generation of proteins toxic to neurons that accumulate over time
may lead to neurodegeneration and are likely to be involved in the
development of late onset MNDs. The numerous gene knockout
lines, generated via a knockout allele in every protein coding gene
in the zebrafish genome (Dooley et al., 2013; Kettleborough et al.,
2013), have the potential to explore long-term phenotypic effects,
as recently demonstrated with adult siblings of mfn2 mutants
(Chapman et al., 2013).
Unlike mammals, zebrafish have the ability to regenerate their
motor circuitry after spinal lesions (Becker and Becker, 2007;
Reimer et al., 2008, 2013), have more extensive neurogenic areas in
the adult brain (Kizil et al., 2012), and is permissive for
regeneration (Fetcho, 2007; Gemberling et al., 2013). However,
it is unable to repair MNDs induced by genetic or environmental
factors, as demonstrated by numerous examples (see Section 5).
3.1.2. Behavioral genetics
In addition to the many genetic tools available, behavioral
genetics are easily accessible in zebrafish. Its stereotyped
movement patterns and tactile response abilities may be used
to model some of the molecular, electrophysiological, and
behavioral aspects of neural diseases (Kalueff et al., 2013; Norton
and Bally-Cuif, 2010; Wolman and Granato, 2012). For example,
larval complex behaviors are composed of simple behavioral
modules that may be associated in a repertoire of stereotyped
motor behaviors (Wolman and Granato, 2012). High-speed
imaging, combined with software for tracking larval movements
at millisecond resolution provides experimenter-independent,
high-throughput screening for motor activity deficits (Burgess
and Granato, 2007a,b; Fontaine et al., 2008; Mirat et al., 2013). For
example, the expression of a human dominant-negative mutation
of KCNC3, found in spinocerebellar ataxia type 13, reduced K+
current amplitude and CaP MN excitability and induced locomotor
deficits in zebrafish (Issa et al., 2011). Physiological analyses
particularly of the NMJ and cellular motor circuits are easily
feasible in zebrafish and more difficult to approach in mouse spinal
cord. The importance of behavioral assessment in MNDs was also
demonstrated in smn mutants where larvae with motor axon
defects had significant motor behavioral deficits (Hao et al., 2012,
2013).
3.1.3. Screening small molecules with toxic or therapeutic effects on
neurons and motor neuron diseases
Zebrafish can be used for high-throughput small-molecule
screening and identification of drugs and chemicals (Kaufman
et al., 2009; Murphey and Zon, 2006; Rihel and Schier, 2012) able to
induce MNDs or rescue an induced MND phenotype, at least in
certain aspects of the disease. Whole organism, in vivo bioassaysmay be performed, usually by waterborne exposure: a library of
small molecules is arrayed in multiwell plates containing zebrafish
embryos or larvae. It should be pointed out that using chemical
libraries that already contain Food and Drug Administration/
European Medicines Agency-approved drugs facilitates the rapid
translation of hits from zebrafish chemical screening to clinical
trials (Tamplin et al., 2012).
The neurotoxic effect of some drugs, chemicals, and environ-
mental toxicants on the development of zebrafish spinal MNs has
been demonstrated. It is easy to analyze the effect of chemicals on
spinal cord MN axonal sprouting and developmental patterns
using transgenic lines with specific promoter-driven expression of
fluorescent proteins or whole-mount immunodetection methods
with PMN or SMN markers, and correlate them with motor
behavior impairments. Fig. 4 summarizes several abnormalities in
the stereotypic pattern of the spinal MN axonal projections in
zebrafish larvae exposed to caffeine and sodium benzoate.
Nicotine, cadmium, ethanol, metam-sodium, and chlorpyrifos-
oxon have also been reported to have neurotoxic effects on spinal
MNs (Kanungo et al., 2011; Menelaou and Svoboda, 2009; Raldúa
et al., 2012; Sylvain et al., 2010; Yang et al., 2011). Moreover,
caffeine and sodium benzoate also induce different defects at
neuromuscular junction (NMJ) level (Chen et al., 2008; Tsay et al.,
2007). Zebrafish represent a suitable model for high-throughput
screening of a library of chemicals to identify those that specifically
impair LMNs. This identification is clearly useful, not only from the
point of view of human risk assessment, but also for the potential
development of toxic models of LMN diseases. Similarities in the
axonal phenotypes after MND-related gene manipulations and
those observed after exposure to some toxicants are striking and
offer an opportunity for understanding how genetic factors
interact with exposure to environmental toxicants and drugs.
Furthermore, one alternative to in vitro target-based drug
discovery is research guided by phenotype in the context of a
whole organism. Thus, animal models of a disease may be used as
tools for therapeutic discovery, provided that they faithfully
reproduce the disease in question. Phenotype-based approaches
may be used to find compounds that modify the disease
phenotype, regardless of the specific molecular targets. Zebrafish
offer a vertebrate model well-suited to very large-scale, pheno-
type-based, small-molecule screening to identify chemical sup-
pressors of disease phenotypes (Lieschke and Currie, 2007; Zon and
Peterson, 2005). The first zebrafish screening for suppression of a
disease phenotype was performed in an aortic coarctation model.
The zebrafish mutation gridlock, affecting hey2, disrupts aortic
blood flow in a physiological manner akin to aortic coarctation in
humans (Peterson et al., 2004). Screening 5000 small molecules led
to the identification of two structurally related compounds that
completely reversed the gridlock phenotype and restored normal
circulation. These compounds induced up-regulation of the
expression of vascular endothelial growth factor (VEGF) and
further experiments demonstrated that the activation of the VEGF
pathway was sufficient to rescue the gridlock phenotype. This first
study demonstrated the utility of zebrafish pharmacological
screening for understanding disease processes and, potentially,
discovering new therapies. Since the original gridlock screen, many
human diseases have been modeled in zebrafish and screening has
been performed to search for suppressors of the disease
phenotypes (Lessman, 2011; Peal et al., 2010).
The development of zebrafish models for studying various
MNDs, such as HSP, SMA, and ALS, opens up the possibility of using
these models for phenotype-driven chemical genetic screens and
finding chemical suppressors of genetic phenotypes. Axonotrophic
compounds that significantly suppressed motor axon defects in a
zebrafish model of SMA were identified after AMO-mediated
reductions in SMN1 (Gassman et al., 2013; Wishart et al., 2014).
Fig. 4. Neurotoxic effect of caffeine and sodium benzoate on the development of
spinal motor neurons in zebrafish. Whole-mount immunofluorescence detection
was performed on 57 hpf zebrafish embryos after rearing in fish water (control, A, B)
or fish water containing 0.77 mM caffeine (C, D) or 6.9 mM sodium benzoate (E, F)
for 31 h. Images are lateral view at the trunk level with anterior part to the right and
dorsal part to the top. Antibodies against synaptotagmin (znp1) (A, C, E) and
neurolin (zn8) (B, D, F) were used to label the axons emerging from the spinal cord
(sc) of primary (PMNs) and secondary motor neurons (SMNs), respectively. (A) In
control embryos, rostral (RoP) (yellow arrow), middle (MiP) (white arrow), and
caudal (CaP) (green arrow) MN axons innervated fast muscle fibers located in the
middle, dorsal, and ventral region of the trunk, respectively. (B) Similarly, axons
from rostral-like, middle-like, and caudal-like SMNs are indicated by yellow, white
and green arrows, respectively. Moreover, at this developmental stage, some
extensions of axonal branching were detected at the CaP and caudal-like SMN axon
levels (white arrowheads). (C) Embryos treated with caffeine exhibited some CaP
MN axons with abnormal morphology (asterisks) and decreased branching.
Moreover, most of the axons of RoP and MiP MNs were absent. (D) Effect of
caffeine on SMNs was consistent with the effects on PMNs, with abnormal
morphology of the caudal-like SMN axons (asterisks). Embryos also exhibited a
complete absence of rostral-like and middle-like SMN axons. (E) Embryos treated
with sodium benzoate exhibited axonal CaP MN overbranching (white arrowhead).
(F) An early truncation of rostral-and middle-like SMN axons was observed. Scale
bar, 50 mm.However, they had no effect on the survival of smn/ larvae
(Gassman et al., 2013). Methylene blue and structurally related
compounds can rescue ALS-like phenotypes associated with
mutant TARDBP and FUS through reduction of the endoplasmic
reticulum (ER) stress response (Vaccaro et al., 2012, 2013).
Dorsomorphin, a small-molecule inhibitor of bone morphogenetic
protein (BMP) type I receptors that inhibits BMP signaling, hasbeen shown to rescue atl1 and pnpla6 morphant phenotypes,
including their spinal motor axon architecture (Fassier et al., 2010;
Song et al., 2013). Epha4 AMO knockdown, as well as the
pharmacological inhibition of EPHA4, a receptor in the ephrin
axonal repellent system, using 2,5-dimethylpyrrolyl benzoic acid,
completely rescued a mutant SOD1-induced motor axonopathy in
zebrafish (Van Hoecke et al., 2012). Similarly, genetic knockdown
and pharmacological inhibition of Epha4 also attenuated the ALS-
induced phenotype in rodents (Van Hoecke et al., 2012),
demonstrating the similar mode of action of this modifying
pathway on axonal degeneration.
3.2. The bad
AMO knockdown technology is still the most common
technique for inhibiting the action of a specific gene or multiple
genes simultaneously during zebrafish development, even if DNA-
based knockout technologies are currently growing. Researchers
must take into account the fact that AMO use has its own
limitations. Inhibition is effective only during the first few days of
development and potential undesirable off-target effects through
p53 activation and neural apoptosis were observed (Bill et al.,
2009; Eisen and Smith, 2008; Robu et al., 2007). Off-target
mediated effects may have contributed to the observed MN
phenotype in tardbp morphants (Hewamadduma et al., 2013;
Schmid et al., 2013). Therefore, this approach may not be suitable
for modeling late onset MNDs, except in cases where late
physiological deterioration is only secondary to early-stage
neurodevelopmental defects, as suggested in a mouse model of
ALS (Martin et al., 2013a,b). In addition, transient AMO models
could not be used in some studies such as survival where knockout
genetics models are needed.
Another, frequently neglected, limitation is that loss or gain of
function of a target gene may result in delayed development, trunk
malformations, and decreases in body length and trunk height.
Defects in MN abundance and axonal length and branching may
not be due to a primary effect on the morphogenesis and
maintenance of MNs but a subsequent indirect or side-effect
leading to a delay in MN emergence. To cite one example among
others, knockdown of the cytochrome c oxidase Vaa subunit using
a specific cox5aa-AMO showed that, although PMN development
was normal at 24 hpf, SMNs, the most similar to mammalian a-
MNs, were severely impaired in number and morphogenesis at
48 hpf (Baden et al., 2007). However, the induced phenotype was
associated with an embryonic malabsorption syndrome (EMS)
(Raldúa et al., 2008), precluding the use of the earlier develop-
mental stages to specifically address the direct effect of a
cytochrome c oxidase deficiency at SMN level but an indirect
effect may have been mediated via nutrient deprivation from the
yolk sac. It is necessary to develop genetic models as a way to
validate the quicker, but sometimes difficult to use, transient AMO
models. As an example, the motor axon defects in the smn AMO
model (McWhorter et al., 2003) were later recapitulated in a
maternal:zygotic-smn mutant (Hao et al., 2013). This is an
important result as it showed that this is not an off target effect
or a secondary defect due to aberrant body morphology. The notion
of secondary defects due to trunk malformations was also
addressed directly in the context of SMA (McWhorter et al.,
2008). Knockdown of gemin2 caused motor axon defects (Winkler
et al., 2005). By performing blastula transplants between gemin2
AMO treated and WT embryos, it was shown that when gemin2 is
knocked down in MNs, they did not display motor axon defects and
when WT MNs were transplanted into gemin2 morphants, they
displayed defects. Thus, the motor axon defects seen in gemin2
AMO animals were due to defects in body morphology and trunk
development.
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Human neurological disorders may be modeled in animals
using standardized procedures that recreate specific pathogenic
events and their behavioral outcomes, but only if there is an
evolutionary conservation of the biological processes involved.
Comparative neuroanatomy between zebrafish and human central
and peripheral nervous systems revealed a similar overall
organization, including cell types and neuron structure acquired
from their last common ancestor, even if the CNS is considerably
smaller in zebrafish than in humans. However, some structural
differences must be taken into account when using the former as a
model for the latter (Leung et al., 2013; Mueller and Wullimann,
2005; Panula et al., 2010; Rinkwitz et al., 2011; Ronneberger et al.,
2012; Wilson et al., 2012; Wullimann et al., 1996). As previously
pointed out (Section 2) (Table 1), a review of the comparative
neuroanatomy of the human and zebrafish motor systems showed
that, while the zebrafish represents a homologous model for LMN
disorders, such as SMA, it is only a partial model for UMN disorders,
due to the absence of corticospinal and rubrospinal tracts in the
zebrafish CNS. However, the zebrafish was recently used as a
relevant model of length-dependent axonopathy of the corticosp-
inal MNs (Section 5), indicating that some deterioration in the
intrinsic properties of MNs are prominent mechanisms underlying
HSPs.
There will probably never be an animal model that is a perfect
fit with the human condition. It was initially asserted that only
non-human primate models were appropriate for testing patho-
physiological hypotheses and evaluating new treatments, while
other model species were only appropriate for the molecular and
genetic exploration of disease mechanisms (Cenci et al., 2002).
After over a decade of using zebrafish as a model for genetic
disorders, it is now clear that this is not only an ideal model for
visualizing development patterns and the associated diseases but
also for studying the functional consequences of mutations of the
human genes implicated in a broad range of degenerative
disorders. However, most of the work published so far used
AMO transient knockdown of target genes at early stages in
development, rather than knockout lines and long-term pheno-
typic surveys. It is, therefore, difficult to detect potential direct or
indirect interactions between developmental and neurodegenera-
tion processes, e.g. EMS (see Section 3.2.), particularly in the
context of late onset MNDs. An AMO model is not a genetic mutant
and therefore the term ‘‘loss of function’’ used by some authors
should be retained only for genetic mutants that have been verified
as loss of function alleles. AMOs more closely resemble to
haploinsufficiency which may not be modeled in homozygous
mutants, which may be too severe, but rather in heterozygotes. The
same precaution may be applied for ‘‘gain of function’’ used instead
of RNA overexpression. In most neurodegenerative diseases,
expression of neurotoxic proteins is a causative factor and the
dominant toxic gain of function ideally requires a heterozygous
model generated through a genome editing method. It should be
also pointed out that some phenotypes elicited by AMO transient
knockdown of target genes involved in neurodegeneration could
not be observed in stable genetic knockout lines (Schmid and
Haass, 2013).
Furthermore, the use of an animal model for identifying
potential molecules to treat patients with diseases does not
change the fact that there is a wide gap between discovering
that a compound is truly effective on an animal model and its
suitability for use in human patients. From this standpoint, the
zebrafish model should be viewed as an easily accessible,
inexpensive, experimental model for screening potential thera-
peutic molecules that must be validated by further studies in
mammals.4. Properties of human and zebrafish motor neurons and
implications for their selective vulnerability to
neurodegenerative diseases
Axon degeneration precedes and, sometimes, causes, neuron
death in several disorders, including MNDs. Thus, the common
pathological feature of HSPs is a progressive ‘‘dying-back’’
degeneration of the longest axons in the CST and posterior
columns. Moreover, other MNDs, such as ALS and SMA, involve
major synapse and axon losses before the appearance of
symptoms, and long before the loss of neurons. For example, in
animal models of ALS, axon loss may reach 60% before the onset of
symptoms (Coleman and Ribchester, 2004; Fischer et al., 2004).
Although axon degeneration is considered a potential therapeutic
target for treating this group of neurodegenerative diseases, new
approaches are needed to elucidate the underlying mechanisms.
Animal models are very useful for replicating cellular correlates of
MNDs such as protein aggregates, inclusions, subcellular defects
and cell death rather than modeling pathophysiology or behavioral
abnormalities that may be species specific.
Recent data indicate that axon degeneration mechanisms are
more uniform than previously thought, even where cause and
histopathology differ widely, as in the case of Wallerian
degeneration and ‘‘dying-back’’ disease. Axons separated from
their cell bodies by nerve transection undergo a program of axon
death known as Wallerian degeneration. Understanding of the
underlying mechanisms of axon degeneration has come mainly
from studying the slow Wallerian degeneration mouse (C57BL/
WldS), a healthy mutant in which Wallerian degeneration is
delayed tenfold. A chimeric WldS protein identified in this mutant
strain inhibits not only Wallerian degeneration but also axon
degeneration in several neurodegenerative diseases. For example,
in crosses of WldS mice with progressive motor neuropathy mice
and the model of Charcot-Marie-Tooth disease (CMT) myelin
protein zero mutant, WldS significantly delayed dying-back axon
degeneration, thus providing a mechanistic link to Wallerian
degeneration (Coleman, 2005). Nevertheless, not all axon degen-
eration is delayed by WldS. An important exception includes mouse
models of MNDs, such as SOD1 transgenic mouse models of ALS
(Velde et al., 2004), the proteolipid protein null model of HSP
(Edgar et al., 2004), and mouse models of SMA (Kariya et al., 2009).
Interestingly, an in vivo zebrafish model of axon degeneration
has been proposed (Bhatt et al., 2004; Feng et al., 2010), based on
axotomy of the Mauthner cell. The transparency of zebrafish
embryos and larvae makes it possible to visualize the soma and
axons of the Mauthner cells directly in vivo, by either back-filling or
single-cell electroporation with fluorescent dyes. The long axon of
this myelinated reticulospinal upper MN regenerates poorly after
spinal lesion, so this model is relevant for studying both axon
degeneration mechanisms and potential therapeutic targets for
axonal regeneration. For instance, using this approach, it was
found that cyclic AMP induced regeneration of zebrafish Mauthner
cell axons in vivo (Bhatt et al., 2004). Moreover, it was recently
demonstrated that, as in mice, overexpression of WldS in the
Mauthner cells delayed axon degeneration in live zebrafish (Feng
et al., 2010).
The characteristic hallmark of human MNDs is the progressive
and highly selective loss of upper and/or lower MNs. But why are
human MNs more susceptible than other neurons or cell types to
some genetic disorders and toxins? Indeed, MN cells are
continuously active, in order to maintain a particular posture or
generate the complex discharge patterns required for locomotor
movements. These large cells, considering the membrane surface,
may have very long axons; indeed, some human UMNs have axons
up to one meter long and axoplasm comprises >99% of total cell
volume (Blackstone, 2012). This implies a high capacity for axonal
transport maintenance, lipid homeostasis, mitochondrial respira-
tion, and ionic gradients across the neuronal membrane, factors
that may be very closely related. An expanding number of proteins
have now been identified that mediate the shaping of the ER
network and are involved in its interaction with the cytoskeleton
and plasma membrane, as well as other dynamic cellular
organelles, such as mitochondria (Goyal and Blackstone, 2013;
Rowland and Voeltz, 2012). Some of these proteins are mutated in
the most common forms of HSPs (Section 5), indicating that proper
ER dynamics, specialization, and distribution are particularly
important in large, highly polarized cells such as MNs (Goyal and
Blackstone, 2013).
Another property of human MNs relevant for their selective
degeneration in MNDs is their high vulnerability to disturbance
of mitochondrial respiration (Cozzolino and Carri, 2012). Not
only do mitochondria provide the main source of energy in the
form of ATP, but they are also the center of the pathway that
regulates apoptosis and calcium homeostasis. Thus, both in vitro
and in vivo, inhibition of mitochondrial respiration induces
selective MN degeneration. Moreover, the disturbance of
mitochondrial respiration sensitizes MNs to stimulation by
glutamate, thus increasing their vulnerability to degeneration
(Lewinski and Keller, 2005).
Although the precise mechanisms leading to selective degen-
eration of MNs are far from being understood, disruptions of
glutamate transmission seem to be involved, together with the
unique properties of human MNs, at least, in ALS and excitotoxic
disorders of UMNs. These properties include weak buffering of
cytosolic Ca2+, the presence of highly Ca2+-permeable a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR),
lacking the GluR2 unit, a high neurofilament content, and an
exceptional vulnerability to mitochondrial function disruption
(Lewinski and Keller, 2005; Weiss, 2011). First of all, disruption of
intracellular Ca2+ homeostasis is thought to play a key role in MN
degeneration. Thus, while Ca2+-binding proteins such as calbindin-
D28k and parvalbumin are absent from human cortical and spinal
MNs, selective targets for MNDs, other infrequently damaged MN
populations express markedly higher levels of these Ca2+-binding
proteins. Although no specific data on calbinding-D28k in
zebrafish is available, this protein is expressed in both primary
and secondary spinal MNs in various fish species (Denizot et al.,
1988). However, in Carassius auratus, a teleost fish species
phylogenetically closely related to zebrafish, calbinding-D28k
(calb1) is not expressed by all the spinal MNs of a similar size and
location (Denizot et al., 1988). Moreover, it has been demonstrated
that Ca2+ signaling is involved in several of the key stages in
zebrafish MN development, including differentiation and axogen-
esis (Ashworth et al., 2001). Thus, due to this specific role during
development, the properties of Ca2+ buffering may be very
different in embryos and adults.
Together with their low cytosolic Ca2+ buffering capacity, the
second property of human MNs that may explain their particular
vulnerability to increased stimulation by glutamate is the fact that
they mainly express the highly Ca2+-permeable AMPAR, with low
levels or total absence of the GluR2 subunits. Thus, the increased
extracellular glutamate levels observed in some MNDs promote
much larger increases in intracellular calcium in human MNs than
in other types of neurons (Van Damme et al., 2002; Vandenberghe
et al., 2000). Expression of gria2a and gria2b, zebrafish paralogous
AMPAR GluR2 subunits, has been found in 72 hpf zebrafish in the
area of the spinal cord where MNs are located (Hoppmann et al.,
2008), although to the best of our knowledge no functional data are
available on the calcium permeability of zebrafish spinal MNs.
However, functional data support the presence of GluR2 subunits
in zebrafish Mauthner cells between 33 and 48 hpf (Patten and Ali,
2007).5. Symptoms of motor neuron degeneration disorders and the
use of zebrafish models
5.1. Upper and lower motor neuron degeneration: amyotrophic
lateral sclerosis
ALS, also known as Charcot’s disease or Lou Gehrig’s disease, is
the most common form of MND, with an incidence rate varying
from 0.3 to 2.5/100,000 (Sathasivam, 2010). The occurrence rate
increases after the age of 40 years, peaks in the late 1960s and early
1970s, and declines rapidly thereafter (Logroscino et al., 2008).
Death occurs in most patients within 2–5 years after diagnosis.
Although the disease is mostly sporadic (s-ALS), 5–10% of cases
appear to be familial (f-ALS) (Kiernan et al., 2011; Rowland and
Shneider, 2001).
ALS is typically characterized by adult-onset degeneration of
the UMNs and LMNs. Disease onset usually begins in the limbs,
termed spinal onset, but about a quarter of ALS patients have
bulbar onset with initial involvement of facial, mouth/jaw and
tongue muscles, associated with poorer prognosis (Pratt et al.,
2012). A hallmark of ALS is rapid progression, with subsequent
spreading to involve other regions, and, over time, most patients
will display both spinal and bulbar features, including emotionali-
ty, yawning, jaw jerking, tongue twitching, wasting, drooling, and
difficulty swallowing. The diagnosis of ALS may be done by
exclusion of other syndromes. The revised El Escorial World
Federation of Neurology criteria are frequently used to established
a diagnosis of ALS (Brooks et al., 2000) but some criticisms have led
to Awaji-shima consensus recommendations, which are likely to
increase the sensitivity of the criteria by the use of electro-
diagnostic findings, without altering their specificity (de Carvalho
et al., 2008).
The pathological hallmarks of ALS are the degeneration and loss
of MNs with astrocytic gliosis. Intraneuronal inclusions are present
in degenerating neurons and glia (Rowland and Shneider, 2001).
TAR DNA-binding protein (TARDBP/TDP-43)-positive ubiquiti-
nated cytoplasmic inclusions are observed in almost all cases of
sporadic s-ALS and in most cases of f-ALS (Neumann et al., 2006).
Fused-in-sarcoma (FUS)-positive inclusions have been identified in
patients with ubiquitin-positive, TARDBP-negative with f-ALS
caused by mutations in FUS (Vance et al., 2009).
The pathophysiological mechanisms underlying the develop-
ment of ALS seem multifactorial and operate through interrelated
molecular and genetic pathways (Kiernan et al., 2011; Robberecht
and Philips, 2013). ALS may be an adult manifestation of a
developmental disorder of the human motor system and various
environmental risk factors have been suggested in s-ALS.
Investigation into susceptibility genes involved in s-ALS has had
little success to date. However, 15 genes and loci of major effects
implicated in f-ALS have been identified in recent years (Table 2).
Mutations in SOD1 coding for the soluble copper/zinc superoxide
dismutase 1, TARDBP and FUS occur in 20% to 30% of f-ALS.
Moreover, expanded GGGGCC (G4C2) hexanucleotide repeats have
been very recently identified within intron 1 of C9ORF72, revealing
the major cause of f-ALS (23–47%) and a genetic cause, which may
also be implicated in s-ALS (4–21%) (Millecamps et al., 2010, 2012).
The pathogenic mechanism, loss or toxic gain of function,
associated with hexanucleotide expansion in C9ORF72 is currently
unknown but even the normal function of this evolutionarily
conserved gene is elusive (Stepto et al., 2014).
There are now several studies using the zebrafish as an in vivo
model for investigating the pathogenesis of ALS (Table 2).
Knockdown of the zebrafish c9orf72 ortholog induced axonopathy
of the MNs and specific locomotor deficits, rescued by expressing
human C9ORF72 transcripts (Ciura et al., 2013). Pathologically
expanded G4C2 RNA transcripts form intranuclear foci, sequester
Table 2
Main genes involved in human ALS determinism, by frequency, and available published data for modeling the pathology in zebrafish.
Gene Sub-type (OMIM) Locus In Onset Pathophysiological mechanisms Freq in f-ALS Freq in s-ALS Ze
C9ORF72 FTDALS (#105550) 9p21 AD A ? (loss of the C9ORF72 encoded protein,
RNA-mediated toxicity, toxic dipeptides
from repeat-associated non-ATG
translation)
20–50% 5–20% 1, 2
SOD1 ALS1 (#105400) 21q22 AD A Detoxification enzyme 10–20% 1–5% 3–10
TARDBP ALS10 (#612069) 1p36 AD A RNA binding and exon skipping 5–15% 1–2% 4, 5, 11–16
FUS ALS6 (#608030) 16q12 AD, AR A RNA binding, exon skipping and DNA
repair
5% <1% 4, 14, 17
ANG ALS9 (#611895) 14q11 AD A Neovascularization 2% 1% NA
PFN1 ALS18 (#614808) 17p13 AD A Disruption of cytoskeletal pathways,
axon outgrowth
1–2% Ex. NA
ALS2 ALS2 (#205100) 2q33 AR J GEF signaling Ex Ex 18
SETX ALS4 (#602433) 9q34 AD J DNA and RNA metabolism Ex Ex NA
VAPB ALS8 (#608627) 20q13 AD A Vesicular trafficking Ex Ex 19
DCTN1 ALS (#105400) 2p13 AD A Axonal transport Ex Ex NA
MAPT ALS-FTD (#600274) 17q21 AD A Microtubule assembly and stability Ex Ex NA
VCP ALS14 (#613954) 9p13 AD A Vesicle transport and fusion,
degradation by the proteasome
Ex Ex NA
OPTN ALS12 (#613435) 10p13 AD, AR A NF-kB/ubiquitin regulation Ex Ex NA
UBQLN2 ALS15 (#300857) Xp11 XL A Ubiquitin-like protein family,
degradation by the proteasome
Ex Ex NA
Abbreviations: A, adult; AD, autosomal dominant; AR, autosomal recessive; Ex, exceptional; Freq, frequency; In, inheritance; J, juvenile; NA, not available; XL, X-linked; Ze,
Zebrafish bibliographic references: 1Ciura et al., 2013; 2Lee et al., 2013; 3Da Costa et al., 2014; 4Kabashi et al., 2011b; 5Laird et al., 2010; 6Lemmens et al., 2007; 7McGown et al.,
2013; 8Ramesh et al., 2010; 9Sakowski et al., 2012; 10Van Hoecke et al., 2012; 11Kabashi et al., 2010b; 12Hewamadduma et al., 2013; 13Schmid et al., 2013; 14Vaccaro et al.,
2012; 15Armstrong and Drapeau, 2013b; 16Vaccaro et al., 2013; 17Armstrong and Drapeau, 2013a; 18Gros-Louis et al., 2008; 19Kabashi et al., 2013.
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zebrafish embryos (Lee et al., 2013). As in mammals, mutations in
zebrafish sod1 have been shown to cause MN loss (Lemmens et al.,
2007). Microinjection of mRNA has been shown to cause transient
overexpression of mutant SOD1 in developing zebrafish embryos
and may confer a toxic-gain-of-function, with abnormal branching
and shortening of MN axons (Lemmens et al., 2007; Sakowski et al.,
2012). Transgenic zebrafish overexpressing mutant SOD1 dis-
played the hallmarks of ALS, including loss of MNs, muscle
degeneration, loss of neuromuscular connectivity and defective
motor performance, and increased stress in the MNs (McGown
et al., 2013; Ramesh et al., 2010; Sakowski et al., 2012). A recent
study where a mutant SOD1 protein was expressed at a
physiological level demonstrated an early altered NMJ morpholo-
gy, a susceptibility to oxidative stress, and an adult onset motor
phenotype that recapitulated the key features of ALS (Da Costa
et al., 2014). Epha4 was first shown to modulate sod1 severity in
zebrafish, and then subsequently shown to correlate with
predisposition in humans, emphasizing the usefulness of this
zebrafish model. Epha4 AMO knockdown as well as the pharma-
cological inhibition of EPHA4 using 2,5-dimethylpyrrolyl benzoic
acid completely rescued a mutant SOD1-induced motor axono-
pathy in zebrafish (Van Hoecke et al., 2012). In humans with ALS,
EPHA4 expression inversely correlates with disease onset and
survival, and loss of function mutations in EPHA4 are associated
with long survival (Van Hoecke et al., 2012). Expression of mutant
TARDBP, encoding TDP-43, a protein found in neuronal inclusion
bodies in patients with ALS and frontotemporal dementia, or
knockdown with an AMO, induced motor neuron axonopathy in
zebrafish embryos (Kabashi et al., 2010b; Laird et al., 2010).
Simultaneous overexpression of human WT TARDBP mRNA versus
mRNAs carrying the mutations showed that the WT mRNA may
rescue the phenotype, whereas the mutant mRNAs may not
(Kabashi et al., 2010b). Expression of WT human TARDBP alone did
not cause a phenotype at the levels used, e.g. to rescue knockdown.
This is important because WT TARDBP induced a phenotype on its
own in other models, i.e. worm, fly and mouse, but not in zebrafish,
emphasizing the greater appropriateness of this model. However, a
recent experiment using knockout loss-of-function tardbp stable
mutants demonstrated no phenotype as a result of compensationby the generation of a novel splice form of the duplicated tardbpl
gene (Hewamadduma et al., 2013). Double-homozygous null
mutants of tardbp and tardbpl had severe developmental abnor-
malities, including impaired spinal MN axon outgrowth (Schmid
et al., 2013). If ALS is due to haploinsufficiency, then the AMO may
model this better than compensation by tardbpl and complete loss
of function of both genes. Progranulin, a neurotrophic factor, with
mutations involved in frontotemporal lobar degeneration, is
required for normal axonal outgrowth in zebrafish embryos.
Knockdown of zebrafish progranulin genes induced MN axono-
pathy, prevented by overexpression of human GRN mRNA
(Chitramuthu et al., 2010; Laird et al., 2010). Co-expression of
human progranulin rescued the axonopathy induced by mutant
TARDBP mRNA in zebrafish embryos, but had no effect on the
mutant SOD1-induced phenotype (Laird et al., 2010). Similarly to
TARDBP, FUS is an RNA binding protein which harbors aggrega-
tion-promoting domains (Li et al., 2013). Knockdown of zebrafish
fus or overexpression of some human FUS alleles on their own
yielded a motor phenotype that was rescued on co-expression of
WT human FUS but not with ALS-related FUS mutations (Kabashi
et al., 2011b). Knockdown and FUS RNA overexpression promoted
abnormal NMJ structure and function (Armstrong and Drapeau,
2013a). WT human FUS rescued the tardbp knockdown phenotype,
suggesting a common pathogenic pathway, while a lack of genetic
interaction between FUS/TARDBP and SOD1 was demonstrated
(Kabashi et al., 2011b). However, co-expression of mutant SOD1
and mutant FUS exacerbated the motor phenotype caused by
overexpression of mutant SOD1 alone (Kabashi et al., 2011b).
Pharmacologically enhanced calcium entry with calcium channel
agonists prevents the NMJ phenotype induced by an ALS human
TARDBP mutation in zebrafish larvae (Armstrong and Drapeau,
2013b). A few other zebrafish genes have been investigated for the
contribution of their loss of function in ALS-related symptoms.
Vapb knockdown led to swimming deficits and the phenotype was
rescued by overexpression of WT human VAPB mRNA, but not by
overexpression of a VAPB mutant (Kabashi et al., 2013). Disruption
in RNA processing is an element in the pathophysiology of several
MN disorders and neurodegenerative diseases. Variants of the RNA
polymerase II component, ELP3, are associated with an increased
risk in ALS patients and knockdown in zebrafish embryos resulted
in motor axonal abnormalities, which may be disease related
(Simpson et al., 2009). AMO-mediated knockdown of zebrafish als2
induced severe developmental abnormalities, swimming deficits
and abnormal MN projections (Gros-Louis et al., 2008) that may be
related to the strongly induced EMS.
5.2. Upper motor neuron degeneration
5.2.1. Hereditary spastic paraplegias
HSPs, also known as familial Strümpell-Lorrain paraplegias, are
a large group of heterogeneous inherited neurological disorders,
characterized by progressive, usually severe, spasticity and
pyramidal weakness, predominantly in the lower limbs (Depienne
et al., 2007; Salinas et al., 2008; Stevanin et al., 2008).
The initial symptoms are usually stumbling and tripping due to
a gait disturbance and stiffness in the legs (Stevanin et al., 2008).
The disease is slowly progressive; most subjects display a
markedly spastic gait and require a cane, walker, or wheelchair
to move. Most patients share the same main features, including
spastic gait, lower-limb hypertonia, hyperreflexia, extensor-
plantar responses, muscle weakness, and bladder dysfunction,
sometimes associated with decreased sensitivity to vibration at the
ankles, and pes cavus or scoliosis. When these signs are isolated,
the disease is described as ‘‘pure’’ or ‘‘uncomplicated.’’ In
‘‘complicated’’ or ‘‘complex’’ forms, additional neurological or
extraneurological features are observed, including mental retar-
dation, peripheral neuropathy, cerebellar ataxia, epilepsy, brain
magnetic resonance imaging anomalies, optic atrophy, retinitis
pigmentosa, deafness, and cataract (Table 3).
Very few neuropathological studies have been performed
(Stevanin et al., 2008). They have revealed dying-back axonal
degeneration preceding cell-body degeneration in the longest
fibers of the corticospinal tracts and dorsal columns, sometimes
associated with loss of cortical neurons and anterior horn cells
(Behan and Maia, 1974; Deluca et al., 2004). The fibers innervating
the lower extremities are the first to be affected, suggesting that
axonal transport, intracellular trafficking, and/or the maintenance
of long fibers are specifically impaired in HSP. This hypothesis was
recently corroborated by the identification of genes involved in
these functions, together with the analysis of animal models.
Indeed, several causative genes (>50) are currently known and
insight into the functions of the proteins they encode have
suggested that, in most cases, intracellular trafficking is affected by
the deterioration of the ER, Golgi apparatus, endosomes, or axonal
transport (Table 2). In addition, myelination, mitochondrial
function, lipid metabolism, protein folding, and axon guidance
may also be disrupted (Depienne et al., 2007; Fink, 2013; Finsterer
et al., 2012; Goizet et al., 2009, 2011; Stevanin et al., 2008).
The stretch reflex is a muscle contraction in response to
stretching within the muscle. This spinal reflex involves a
monosynaptic pathway providing automatic regulation of muscle
length. Type Ia afferent fibers from muscle spindles of one muscle
make excitatory connections not only with the a-MNs innervating
the same muscle but also with those innervating the synergic
muscles. Moreover, via type Ia inhibitory interneurons, type Ia
afferent fibers inhibit antagonistic muscles. When a muscle is
stretched, type Ia afferent neurons increase their firing rate,
leading to the contraction of the same muscle and its synergics and
the relaxation of the antagonist, in a reaction known as reciprocal
innervation. Type Ia inhibitory interneurons involved in the stretch
reflex also receive inputs from the collateral fibers of some axons of
the corticospinal tracts, making direct excitatory connections with
spinal a-MNs. In this way, type Ia inhibitory interneurons are used
to coordinate muscle contraction during voluntary movements.
Axons from some brainstem descending tracts also have excitatory
and inhibitory connections to this interneuron. Thus, the stretchreflex is mediated by multiple pathways acting in parallel via
spinal and supraspinal pathways. Reflex responses mediated via
supraspinal structures are known as ‘‘long-loop reflexes’’. While
subcortical reflex pathways may be responsible for the afferent
regulation of proximal muscle contractions, cortical projections
may be of primary importance in modulating distal muscle
contractions. Lesions in the supraspinal structures involved in
long-loop reflexes may result in either hyperactivity or hypoac-
tivity of the stretch reflexes.
The stretch reflex feedback loop provides the higher centers of
the nervous system with a mechanism for adjusting muscle tone
under different circumstances. Muscle tone disorders are fre-
quently associated with lesions in the supraspinal descending
pathways controlling the stretch reflex. Spasticity is a muscle tone
disorder characterized by hyperactive tendon jerks and an increase
in resistance to rapid muscle stretch. Partial denervation of the
spinal neurons involved in the stretch reflex, inhibitory inter-
neurons, and a- and g-MNs leads to a gradual increase in
sensitivity of these neurons. The synaptic contacts of UMNs are
replaced by synapses with spinal cord neurons, resulting in a
gradual increase in the influence of the reflexes on a-MN activity,
reflected by the appearance of hyperreflexia. The increased
influence of the muscle spindle results in massive contraction
on stretching. Nevertheless, the muscle spindle response is mainly
phasic, so when the muscle is stretched slowly or continuously, its
activity decreases and the influence of the Golgi tendon organ
becomes dominant, inhibiting the muscle contraction via the IIa
inhibitory interneuron.
Key differences in human and zebrafish neuroanatomy of the
cortical descending pathways preclude the use of zebrafish as a
homologous model for UMN diseases, such as HSP. Nevertheless,
zebrafish still represent a suitable partial model for a molecular
and genetic dissection of the mechanisms involved in UMN
disorders. Proprioceptors like the muscle spindle are not found in
zebrafish myotomal muscle (Drapeau et al., 2002). Accordingly, the
stretch reflex does not exist in zebrafish. The absence of both the
corticospinal tract and stretch reflex preclude the possibility of
reproducing the spasticity per se, the key diagnostic clinical finding
of UMNs disorders in humans, in zebrafish. In fact, the spastic-like
phenotypes described in some mutants (tnt, roc) or after treatment
with strychnine are not really related to spasticity sensu stricto, but
to other types of motor overactivity (Granato et al., 1996; Hirata
et al., 2010). It is well established that strychnine induces motor
overactivity by blocking the glycine function and a similar
mechanism has been proposed for these two spastic-like mutants
(Granato et al., 1996).
A functional analysis helps to demonstrate the causal relation-
ship between defect and mutation. An identified HSP gene
mutation in humans has been shown to induce pathogenic
mechanisms in zebrafish, including MN axon defects, sometimes
accompanied by locomotor impairment. Knockdown of atl1
(SPG3A, atlastin) caused an abnormal MN axon architecture,
correlated with a decrease in larval mobility, and genetic or
pharmacological inhibition of the BMP signaling pathway rescued
the induced phenotype (Fassier et al., 2010). Knockdown of spast
(SPG4, spastin) inhibited spinal MN axon outgrowth and reduced
axonal microtubule networks, causing extensive CNS-specific
apoptosis and motility defects (Wood et al., 2006; Allison et al.,
2013). Axon outgrowth defects were exacerbated by immersion of
spast-morphant embryos in embryo medium containing the
microtubule-destabilizing drug nocodazole (Butler et al., 2010).
Simultaneous knockdown of katna1, encoding katanin p60, also
involved in microtubule dynamics, and spast, exacerbated defects
in spinal MN axon outgrowth (Butler et al., 2010). Protrudin
(ZFYVE27, zinc finger, FYVE domain containing 27) may interact
with spastin to modulate neurite outgrowth, as suggested by the
Table 3
Main genes involved in HSP determinism and available published data for modeling the pathology in zebrafish (for published data on other zebrafish HSP genes, see text).
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BSCL2 (Seipin) SPG17 (270685) 11q12.3 Protein located in the
membrane of ER
Rare Variable Silver syndrome: distal
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CYP7B1 (CYP7B1) SPG5 (270800) 8q12.3 Cholesterol et
neurosteroid metabolism
7% (1–3% in sporadic
cases)





PGN (Paraplegin) SPG7 (607259) 16q24.3 Mitochondrial ATPase 8–21% (up to 7% in
sporadic cases)







KIAA1840 (Spatacsin) SPG11 (604360) 15q21.1 Endosomal trafficking 21–26% (42–78% of HSP
with TCC or ID)
1–30 Cognitive Tr or ID,
peripheral neuropathy, RP
(Kjellin syndrome),





ZFYVE26 (Spastizin) SPG15 (270700) 14q24.1 Endosomal trafficking,
mitochondrial
dysfunction
2–5% (5–11% of HSP with
TCC or ID)
4–19 Cognitive Tr or ID,
peripheral neuropathy, RP
(Kjellin syndrome),





L1CAM SPG1 (303350) Xq28 Adhesin, neuritic growth,
myelination









Abbreviations: AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AR, autosomal recessive; CMT, Charcot-Marie-Tooth, MASA syndrome, Mental retardation,
Aphasia, Shuffling gait, Adducted thumbs; CRASH syndrome, Corpus callosum hypoplasia, Retardation, Adducted thumbs, Spastic paraparesis, and Hydrocephalus; ER,
endoplasmic reticulum; ID, intellectual deficiency; L1CAM, L1 cell adhesion molecule; NA, not available; REEP1, receptor expression-enhancing protein 1; RP, retinitis
pigmentosa; TCC, thin corpus callosum; Tr, troubles; UL, upper limbs; Ze, Zebrafish bibliographic references: 1Fassier et al., 2010; 2Allison et al., 2013; 3Butler et al., 2010;
4Wood et al., 2006; 5Zhang et al., 2012; 6Valdmanis et al., 2007; 7Martin et al., 2012; 8Southgate et al., 2010; 9Wolman et al., 2007; 10Brösamle, 2010.
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injection of human WT spastin and protrudin (Zhang et al., 2012).
Vacuolar protein sorting 37A (SPG53) is another protein involved
in the endosomal sorting complex required for the transport
system. A loss of motility was induced in vps37a knockdown AMO-
injected zebrafish embryos without obvious dysmorphology, thus
supporting the causal relationship between mutations in this gene
and the spastic paraparesis described in patients (Zivony-Elboumet al., 2012). Knockdown of the zebrafish homolog of KIAA0196
(SPG8, strumpellin) induced a curly-tail phenotype coupled with
shorter motor axons. This phenotype was partially rescued by the
human WT strumpellin but not the two mutants identified in HSP
patients (Valdmanis et al., 2007). Similarly, AMO knockdown of
SLC33A1 (SPG42, solute carrier family 33 (acetyl-CoA transporter),
member 1) in zebrafish embryos caused a curly-tail phenotype and
defective axon outgrowth from the spinal cord. WT human
SLC33A1, but not a mutant form correlated with HSP, was able to
rescue the morphant phenotype (Lin et al., 2008). However, the
view that SLC33A1was equivalent to the SPG42 gene has been
recently challenged (Huppke et al., 2012). The zebrafish is a
powerful in vivo system for testing genetic interactions. Disruption
of spg11 (SPG11, spatacsin) or zfyve26 (SPG15, spastizin) expres-
sion during zebrafish development induced a range of develop-
mental defects, including locomotor impairment and abnormal
architecture of spinal MN axons (Martin et al., 2012; Southgate
et al., 2010). These two proteins are components of a multi-protein
complex (Słabicki et al., 2010) and AMOs targeting the two genes at
the same time suggested that they were involved in a pathway
required for spinal MN axon outgrowth (Martin et al., 2012).
However, an EMS (Raldúa et al., 2008) was apparently induced by
changing the expression of these genes, thus making it difficult to
interpret the phenotype, which may also be due to a developmen-
tal delay. Similarly, knockdown of slc16a2 (SPG22, solute carrier
family 16, member 2), the functional ortholog of human MCT8
thyroid hormone transporter (Arjona et al., 2011), caused
developmental and neurological impairment (Vatine et al.,
2013). Disturbance of the lipid metabolism is emerging as a
subset of HSP types (Tesson et al., 2012). Some of the normal-
looking gba2 morphant embryos (SPG46, glucosidase, beta (bile
acid) 2) exhibited abnormal locomotion and outgrowth of spinal
MNs (Martin et al., 2013a,b). Mutations of PNPLA6 (SPG39, patatin-
like phospholipase domain containing 6) result in autosomal
recessive HSP and this protein may also be one of the targets for
distal damage to the longest axons induced by neuropathic
organophosphorus compounds and chemical warfare agents
(Glynn, 2013). Knockdown of the zebrafish homolog induced a
strong developmental phenotype associated with impairment of
MN axon development and an increase in axonal truncation and
branching (Song et al., 2013). This phenotype was rescued by the
introduction of WT, but not mutant, human PNPLA6 mRNA.
Knockdown modeling in zebrafish has been recently used for a
functional validation of new candidate genes, e.g. ARL6IP1 (SPG61,
ADP-ribosylation factor-like 6 interacting protein 1), PGAP1
(SPG67, Post-GPI attachment to protein 1), and USP8 (SPG59,
Unbiquitin specific peptidase 8) identified by whole-exome
sequencing of HSP documented consanguineous human families
(Novarino et al., 2014).
5.2.2. Primary lateral sclerosis
Primary lateral sclerosis (PLS) [OMIM#611637] is a pure UMN
syndrome, characterized by progressive UMN degeneration with
limb and bulbar dysfunction, but no LMN features (Sathasivam,
2010). PLS is generally considered a rare presentation of ALS with
pure UMN involvement (Kiernan et al., 2011). Whether PLS is a
separate entity from the ALS variant, or simply a different
manifestation of this MND, remains controversial.
Patients with PLS tend to present 5–10 years earlier than those
with ALS, have less limb wasting and bulbar symptoms during the
course of the disease, and survive 6–7 years longer (Gordon et al.,
2006; Tartaglia et al., 2007). To date, no genetic causes have been
associated with PLS and therefore no data are available on
zebrafish.
5.3. Lower motor neuron degeneration
5.3.1. Spinal muscular atrophy
SMA is a clinically and genetically heterogeneous disease,
characterized by the degeneration of a-MNs in the ventral horn of
the spinal cord, leading to progressive atrophy of skeletal muscles
and paralysis (D’Amico et al., 2011). The most frequent form is
inherited as an autosomal recessive trait, resulting from mutations
in SMN1 encoding for survival of motor neuron 1 (Burghes andBeattie, 2009; Lefebvre et al., 1995), and represents the second
most common fatal autosomal recessive disorder after cystic
fibrosis, with an incidence of 1/6000–1/10,000 live births (D’Amico
et al., 2011). In fact, the term ‘‘SMA’’ is now reserved for SMN1-
related SMA, all other forms being exceptional. Severe generalized
muscle weakness and atrophy, predominantly in proximal limb
muscles, are the hallmark of the disease. The phenotype is
classified into four grades of severity (SMA types 1, 2, 3, and 4),
based on age of onset and motor function achieved (D’Amico et al.,
2011; Zerres et al., 1997). SMA type 1 (Werdnig-Hoffmann disease)
[OMIM#253300] is the earliest, most severe, and most common
type. Onset is before 6 months of age: patients never sit up and
generally do not survive beyond the first 2 years. SMA type 2
(intermediate form) [OMIM#253550] is characterized by onset
between 7 and 18 months. Patients do not achieve the ability to
walk independently and the course of the disease is severe.
Patients with SMA type 3 (mild, Kugelberg-Welander disease)
[OMIM#253400] display highly variable severity of the disease,
with an age of onset after 18 months. Proximal muscular weakness
occurs during infancy. Some patients require wheelchair assis-
tance while others continue to walk in adulthood with only minor
muscular weakness. SMA type 4 has been added to this
classification to describe with adult onset and mild course,
without any risk of respiratory and nutritional troubles. All types
of SMA are caused by homozygous deletion or mutation of SMN1
(Hamilton and Gillingwater, 2013). In humans, there are two
survivals of motor neuron genes: telomeric SMN1 and its
centromeric homolog SMN2, caused by the intrachromosomal
duplication of 5q13. A single C to T substitution at base pair
position 840 in SMN2 compared to SMN1 results in the exclusion of
exon 7 from approximately 85–90% of SMN2 transcripts. About 95%
of patients have a homozygous disruption of SMN1 due to deletion
or gene conversion of SMN1 to SMN2 (Feldkotter et al., 2002). About
3% of affected individuals are compound heterozygotes for deletion
of one SMN1 allele and intragenic mutations. Loss of SMN1 is
essential to the pathogenesis of SMA, while the severity of the
disease is primarily related to the number of copies of SMN2.
Non-SMN1 or non-5q SMA (or SMA plus phenotypes) have
progressively become increasingly important (Guillot et al., 2008).
Some have been accepted as separate entities definitely not linked
to chromosome 5q markers (Zerres and Rudnik-Schoneborn,
2003). Among them, spinal muscular atrophy with respiratory
distress (SMARD 1) [OMIM#604320] is a very rare autosomal
recessive disorder. The onset is very early, characterized by initial
respiratory insufficiency due to diaphragmatic palsy, symmetrical
distal muscular weakness, muscle atrophy, peripheral sensory
neuropathy, and autonomic nerve dysfunction (Grohmann et al.,
2003; Kaindl et al., 2008). The prognosis is poor with early death.
Survival up to a few years has been reported only with assisted
ventilation. The causative gene, IGHMBP2, encodes immunoglobu-
lin m-binding protein 2, located on chromosome 11q13 (Grohmann
et al., 2001). Lethal congenital contracture syndrome 1 (LCCS1)
[OMIM#253310] is an exceptional autosomal recessive condition
with prenatal onset, leading to total immobility of the fetus,
accompanied by hydrops, micrognatia, pulmonary hypoplasia,
pterygia, and arthrogryposis (Makela-Bengs et al., 1998). It
invariably leads to prenatal death before the 32nd gestational
week. Neuropathological analysis reveals a lack of anterior horn
motoneurons, severe atrophy of the ventral spinal cord, and
hypoplastic, almost absent skeletal muscles (Herva et al., 1988). A
milder phenotype, lethal arthrogryposis with anterior horn cell
disease (LAAHD), is characterized by fetal akinesia, arthrogryposis,
and MN loss, leading to early death following respiratory failure
after the delivery (Nousiainen et al., 2008). Neuropathological
findings in LAAHD resemble those of LCCS1, but are less severe.
Mutations in the GLE1 RNA export mediator are the cause of these
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atrophy with progressive myoclonic epilepsy (SMA-PME)
[OMIM#159950] is also extremely rare (Haliloglu et al., 2002;
Jankovic and Rivera, 1979). Affected patients display severe,
progressive myoclonic epilepsy and LMN disease, proven by
electrophysiological and muscle-biopsy findings. The course of the
disease is severe, leading to respiratory muscle involvement and
severe handicap or death before 20 years of age. Mutations in the
ASAH1 gene have very recently been demonstrated to cause SMA-
PME (Zhou et al., 2012). Mutations of the same gene are
responsible for Farber disease, a very rare autosomal recessive
condition resulting from a marked reduction in lysosomal acid-
ceramidase activity (under 10%) or its total absence. Farber disease
is characterized by early onset subcutaneous lipogranulomata,
joint pain, and hoarseness of the voice. A higher residual acid-
ceramidase activity might be responsible for SMA-PME. It should
be pointed out that the distinction between developmental and
degenerative conditions is becoming less and less clear in
neurological conditions. Indeed SMA type 1, SMARD1, LCCS1,
and SMA-PME have very early, sometimes prenatal, onset and are
clearly related to an MN development disorder, but these
abnormally developed MNs will ultimately degenerate. These
clinical conditions are now included by all authors in MNDs.
PCH1 [OMIM#614678] is a distinctive subtype of pontocer-
ebellar hypoplasia (PCH) only diagnosed in 13 unrelated families
from around the world, characterized by congenital onset of
diffuse muscle wasting secondary to spinal cord anterior horn cell
loss and cerebellar hypoplasia (Wan et al., 2012). Neurogenic
muscle atrophy with spinal motor neuron disease has been
confirmed by electromyography, muscle biopsy, or autopsy.
Exome sequencing has identified recessive mutations in EXOSC3,
coding for exosome component 3, highlighting the implication of
RNA processing dysregulation in the abnormal development and
degeneration of cerebellar and spinal motor neurons (Wan et al.,
2012).
Autosomal dominant SMA (AD-SMA), also known as dominant
congenital SMA (DCSMA) or autosomal dominant lower extremity-
predominant spinal muscular atrophy-2 (SMALED2)
[OMIM#615290], is a very rare disorder of developing anterior
horn cells, characterized by congenital onset with predominantly
proximal lower-limb features and very slow progression through-
out life (Peeters et al., 2013). Clinical overlaps with HSP and DCSMA
with upper motor neuron have been highlighted in the 8 affected
families reported to date (Oates et al., 2013; Neveling et al., 2013).
In these families, heterozygous dominant mutations have been
identified in BICD2, encoding bicaudal D homolog 2 (Drosophila), a
key adaptor protein that interacts with the dynein–dynactin motor
complex, which facilitates the intercellular trafficking critical to
motor neuron development and maintenance (Oates et al., 2013).
SMA and other lower MNDs are clinically characterized by
muscle atrophy and muscle weakness, probably resulting from
skeletal muscle denervation (Nicole et al., 2002). Denervation,
defined as an NMJ unoccupied by a-MNs, is common in lower
MNDs. Thus, after a short presymptomatic period, mutant mice
with an intermediate phenotype began to have difficulty
ambulating and righting themselves. Histological analysis of
skeletal muscle at 2 weeks revealed atrophy, with denervated
neuromuscular junctions and reduced acetylcholine receptor
(AChR) clusters (Lee et al., 2013). The extent of denervation
generally correlates with the degree of severity in mouse SMA
models (Kariya et al., 2008).
Zebrafish has been used as a vertebrate model of SMA by using
AMO to reduce the survival of motor neuron protein levels or
generating smn (smn1) mutants, although smn AMO exhibited
defects in spinal LMN axon outgrowth and pathfinding (Carrel
et al., 2006; McWhorter et al., 2003; Oprea et al., 2008; Winkleret al., 2005). The zebrafish phenotype was rescued by full length
human SMN but not the mutated version (Carrel et al., 2006).
When zebrafish smn morphant NMJs were analyzed at 3 dpf, both
normal and aberrant axons colocalized with AChR clusters,
suggesting that although smn AMO did not have the stereotyped
pattern of innervations, the muscle fibers were innervated by
axons (McWhorter et al., 2003). Similarly, the presynaptic marker
synaptic vesicle protein 2 (SV2) colocalized with AChR clusters and
no NMJ defects were observed in 9 dpf smn mutants with reduced
levels of survival motor neuron protein (Boon et al., 2009).
However, in 11 dpf smn mutants, a marked decrease in SV2 was
found at the NMJ. Interestingly, other presynaptic markers, such as
synaptotagmin II and synaptophysin, were unaffected (Boon et al.,
2009). Decreased size and low activity has been described in these
smn mutants. When mutants were generated lacking both
maternal and zygotic SMN there was very low levels of SMM
protein and the mutants display motor axon defects (Hao et al.,
2013). This maternal:zygotic-smm zebrafish mutant has low levels
of SMN due to the leaky heat shock promoter driving human SMN
and thus is a true, severe genetic model of SMA. Conditional
transgenesis revealed that SMN protein was needed during the
whole MN morphogenesis process and to rescue motor axon
defects and motor deficits on a zebrafish null smn mutant
background (Hao et al., 2013). This suggests that an early
developmental defect in MNs through a low level of SMN may
have a long-term deleterious effect on connectivity and move-
ment. A depressed actin-binding and bundling protein, plastin 3
(PLS3), level has also been found in smn mutants and this protein
was able to rescue axon growth defects associated with low SMN in
zebrafish (Hao et al., 2012; Oprea et al., 2008). This protein acts as a
protective modifier of SMA in improving axon outgrowth,
counteracting poor axonal connectivity at SMA NMJs (Ackermann
et al., 2013; Oprea et al., 2008) through is Ca2+ binding residues
(Lyon et al., 2014). Consequently, zebrafish represent a suitable
model for finding SMN1 interacting partners able to modulate an
SMN1-deficiency phenotype (Akten et al., 2011; Lotti et al., 2012).
As it has been demonstrated that transgenic zebrafish expressing
human SMN2 rescued the neuromuscular presynaptic SV2 defect in
smm mutants and increased their survival (Hao et al., 2011), a
genetic model of SMA has been implemented in zebrafish. Novel
candidate genes implicated in SMA phenotype have been
identified in transcriptome analyses of SMN deficient zebrafish
(See et al., 2014). Whole embryos rather than isolated motor
neurons were used in this approach to take into consideration
transcripts expressed in non-MN cell types potentially able to
mediate non-cell autonomous effects. Neurexin2a was identified
as a strongly down-regulated gene and the knockdown of nrxn2a
resulted in motor CaP MN axon truncations and branching defects
and phenocopies of SMN defects, including reduced motor axon
excitability (See et al., 2014). The partial rescue of SMN morphants
by nrxn2ab mRNA injection strongly suggested that nrxn2a acted as
a downstream SMN mediator. Chondrolectin is a gene identified in
a splicing array to be decreased in mouse SMN mutants and
knockdown and overexpression in zebrafish embryos indicated a
role in MNs axon maintenance as well as pathfinding (Zhong et al.,
2012). MN axon defects caused by smn AMO can be rescued by
chodl overexpression supporting chondrolectin as an in vivo
genetic modifier of the SMA phenotype (Sleigh et al., 2014). The
involvement of ubiquitin homeostasis and b-catenin signaling has
been also explored by using a zebrafish model of SMA (Wishart
et al., 2014).
Although muscle atrophy, measured as a decrease in muscle
fiber size, is an easy endpoint to analyze in zebrafish (Cao et al.,
2009; Hanai et al., 2007), to the best of our knowledge, no
information is currently available on muscle atrophy in zebrafish
models of SMA. Therefore, zebrafish is a very useful homologous
model for LMN diseases, although additional efforts should be
made to analyze the clinical features of this group of diseases,
muscle atrophy and weakness.
It should be pointed out that the zebrafish has been used as a
functional validation test for deciphering the effect of rare human
variants associated with LMN diseases. GLE1 depletion in zebrafish
embryos induced an LCCS1-like phenotype and apoptosis of neural
precursors leading to defective spinal MNs (Jao et al., 2012). AMO
knockdown of asah1b, a homolog of human ASAH1 associated with
SMA-PME, led to a marked loss of MN axonal branching and a
concomitant increase in apoptosis in the spinal cord (Zhou et al.,
2012). AMO knockdown of exosc3 in zebrafish embryos caused
general embryo maldevelopment similar to EMS, resulting in small
brain size and poor motility, reminiscent of some human clinical
features of PCH1, and these defects were largely rescued by co-
injection with human WT but not mutant exosc3 mRNA (Wan et al.,
2012).
5.3.2. Distal hereditary motor neuropathy, spinal Charcot-Marie-
Tooth disease, or distal spinal muscular atrophy
Distal hereditary motor neuropathy (dHMN), also referred to as
distal SMA or spinal CMT, represents a group of clinically and
genetically heterogeneous diseases caused by degeneration of
spinal motor neurons (Devic et al., 2012; Rossor et al., 2012). Spinal
CMT is defined by a slowly progressive, symmetrical, predomi-
nantly distal lower motor neuron phenotype. Electroneuromyo-
grams reveal pure motor neuropathy. Many forms of dHMN have
minor sensory abnormalities and/or a significant upper-motor-
neuron component, and there is often an overlap with the
dominant axonal forms of CMT (CMT2), juvenile forms of ALS,
and HSP. Eleven causative genes and four loci have been identified
with autosomal dominant, recessive, and X-linked inheritance
patterns (Table 4). The encoded proteins are implicated in protein
misfolding, axonal transport, RNA metabolism, cation-channel
function, and mitochondrial network maintenance mechanisms
that overlap with other MND.Table 4
Main genes involved in dHMN determinism and available published data for modeling
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references: 1Langworthy and Appel, 2012; 2Del Bene et al., 2008; 3Amato et al., 2012.Modeling CMT2 in zebrafish by inducing mutations in LRSAM1
produced a modified phenotype of lrsm1 morphants associated
with abnormal MN development (Weterman et al., 2012).
Homozygous deletions of Mfn2 in mice cause placental abnormal-
ities and embryo death (Chen et al., 2003), thus precluding the use
of this animal as a model for CMT2A2. AMO targeting a splice site of
zebrafish mfn2 showed severe, early developmental effects,
including truncated MNs, fewer NMJs, and abnormal muscle fibers
(Vettori et al., 2011). In contrast, mfn2 null allele embryos initially
appeared healthy but exhibited a progressive loss of motor
function with defective axonal transport of mitochondria and
alterations at the NMJ level (Chapman et al., 2013).
5.3.3. Spinal and bulbar muscular atrophy
Spinal and bulbar muscular atrophy (SBMA) [OMIM#313200], or
Kennedy’s disease, is an adult-onset disorder affecting both muscle
and LMNs (Kennedy et al., 1968). Patients present amyotrophic,
proximal or distal weakness and wasting of the facial, bulbar and
limb muscles, as well as occasional sensory disruptions, associated
with endocrine disturbances, including androgen resistance, gy-
necomastia, elevated testosterone or progesterone, and reduced
fertility (Finsterer, 2009; Kennedy et al., 1968). The course is slowly
progressive; the ability to walk lost only late in life; only few patients
require ventilator support, and life expectancy is only slightly
reduced. SBMA is an X-linked recessive polyglutamine disorder
caused by expansion of a polymorphic CAG tandem-repeat in exon 1
of the androgen-receptor gene (La Spada et al., 1991). The cardinal
histopathology findings are loss of anterior horn cells in the brain
stem and spinal cord.
5.3.4. Other motor neuron syndromes
The Brown-Vialetto-Van Laere (BVVL) [OMIM#614707] and
Fazio-Londe syndromes (FL) [OMIM#211500] are very rare motor
neuron disorders with clinical overlap, as they share bulbar palsy
and respiratory insufficiency (Bosch et al., 2012; Ciccolella et al.,
2012). In BVVL, a sensorineural deafness is observed in addition to the pathology in zebrafish.
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The age at onset is highly variable, ranging from infancy to
adulthood. Classically, a sensorineural hearing loss is the sign at
onset in BVVL, followed by other lower cranial nerve involvement
and lower motor neuron symptoms in the limbs (Spagnoli and De
Sousa, 2012). Upper motor neuron symptoms are less frequently
described. In FL, earlier onset is generally associated a more rapidly
progressive course, leading to respiratory distress, and weakness in
the face and all four limbs, but mainly the upper limbs. BVVL and FL
are caused by riboflavin deficiency secondary to mutations in one
of the following three genes: SLC52A3, SLC52A2 and SLC52A1, each
them coding for a riboflavin transporter. Oral riboflavin supple-
mentation seems to stabilize and improve progression of the
disease.
Triple A syndrome (3A syndrome or Allgrove syndrome)
[OMIM#231550], is a rare autosomal recessive disorder charac-
terized by adrenocorticotropic hormone resistant adrenal defi-
ciency, achalasia of the esophageal cardia, and alacrimia (Allgrove
et al., 1978). Autonomic and neurological dysfunction, including
UMNs and LMNs involvement, frequently complete the clinical
spectrum (Goizet et al., 2002; Houlden et al., 2002; Messina et al.,
2009). 3A syndrome is caused by mutations in AAAS gene coding
for ALADIN, a ubiquitous protein containing four WD repeats,
aimed to form a typical b-propeller structure (Tullio-Pelet et al.,
2000). WD repeats typically occur multiple times within a protein.
These domains are involved in protein–protein interactions that
may act in signal transduction, intracellular trafficking, cytoskele-
ton assembly, transcription, and cell division control (Smith et al.,
1999). There are currently no data on modeling SBMA, BVVL, FL,
and 3A syndrome in zebrafish but this animal may be used to
dissect the molecular mechanisms involved.
6. Some future prospects
Recent technological advances and intrinsic qualities of the
zebrafish, e.g. rapid, external development and optical observation
both early and late organogenesis stages, using adult transparent
casper or pinky lines (Hsu et al., 2013; White et al., 2008), make this
experimental model of major significance for biomedical research in
general and MNDs in particular. Techniques including labeling
different cell types and distinct subcellular compartments in live
fluorescent transgenic reporters, the use of in vivo two-photon
microscopy, laser ablation, Ca2+ imaging, and patch clamp electro-
physiology, even in the embryonic and larval stages, has made it
possible to characterize the in vivo dynamics of processes in neurons
and neural networks and early neurological changes in diseases. For
example, the transgenic mitofish line has made it possible to study in
vivo mitochondrial distribution and transport in Rohon-Beard sensory
neurons, as well as some induced defects in a tauopathy model
(Plucińska et al., 2012). This approach may be combined with vital
dyes for cellular, subcellular, and functional imaging (Romanelli et al.,
2013). New in vivo non-invasive technologies, including conditional
transgenesis (Hans et al., 2011) and optogenetics (Arrenberg and
Driever, 2013; McLean and Fetcho, 2011) are emerging for monitoring
the temporal requirements of MN development and survival, as well
as motor neuron activities. This has recently been demonstrated in the
case of the requirement of SMN1 for proper MN morphology in
embryonic stages with long-term effects (Hao et al., 2013) and to
identify brain (Ahrens et al., 2013; Sumbre and Poo, 2013) and spinal
cord (Fajardo et al., 2013; Fidelin and Wyart, 2014; Kimura et al.,
2013; Wyart et al., 2009) neurons critically involved in locomotor
drive. These approaches may be used for in vivo imaging and
monitoring the dynamics of the appearance of neurodegenerative
disease-related biological processes.
Zebrafish have a very interesting potential for testing whether
mutations that represent risk factors with low penetrance and/orthat generate compounds toxic to neurons and accumulate over
time may cause MNDs to be more deleterious with additional
genetic variants and/or combine with environmental factors that
enhance the risk. The knockdown of epha4 or its pharmacological
inhibition using 2,5-dimethylpyrrolyl benzoic acid rescued the
axonopathy induced by mutant SOD1 and TARDBP expression, as
well as the motor axon phenotype induced by knockdown of smm1
(Van Hoecke et al., 2012). The excitotoxic effects of calcium are
well described for late stages of ALS manifestation, i.e. leading to
cell death, but the opposite may be true at earlier, pre-clinical
stages which are the most important for drug development.
Calcium channel agonists protect against neuromuscular dysfunc-
tion in a zebrafish model of TARDBP mutation (Armstrong and
Drapeau, 2013b). In addition, the antiexcitotoxic drug riluzole, that
inhibits neuronal sodium channels in zebrafish (Tong and
McDearmid, 2012) and is an approved drug for use in ALS, and
apomorphine, known to be an activator of the NRF2 antioxidant
response, were able to reduce the neuronal stress in a sod1
zebrafish model of ALS (Da Costa et al., 2014; McGown et al., 2013).
These findings demonstrated the potential of this model to identify
modifier genes and chemical suppressors of disease phenotypes
that generically modulate the vulnerability of neurons to
degeneration. The ease of performing whole-organism, in vivo
bioassays of zebrafish offers an unparalleled opportunity for
understanding how genes and their variants interact with
exposure to environmental toxicants and drugs, either to preserve
health or cause disease. This good predictive model may be
relevant for MNDs with a high incidence of sporadic cases, such as
ALS (Chang and Wu, 2009; Trojsi et al., 2013).
In conclusion, genetic analyses in humans together with in vitro
and in vivo studies using model systems, like mice and zebrafish,
have greatly expanded our knowledge of MNDs. As described in
this review, the zebrafish has been used to study molecular and
functional aspects of some MNDs in an in vivo context. However,
this type of research is still in its infancy: relatively few human
mutations have been investigated to date and there is great
potential for combining different approaches to discover new
genetic and environmental factors, alone or in combination. The
model also offers very promising avenues for deciphering the in
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